Targeting an Immune Regulating Protein May Help Halt Glioblastoma Progression
Investigators working on Glioblastoma Moon Shot program have made a key discovery on glioblastoma progression, identifying a key target to help stop it.
Engineered Cancer Antivirus Has Antisarcoma Effect
The oncolytic adenovirus was safe in terms of toxicity in mice models.
Therapeutic Target for Medulloblastoma Identified in Mice Models
The medulloblastoma subset has a poor prognosis, so investigators have been looking for new treatment options.
FDA Approves Ibrutinib/Obinutuzumab for Treatment-Naive Patients with Chronic Lymphocytic Leukemia
The FDA has approved Janssen’s ibrutinib plus obinutuzumab for treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Refining Leukemia Classification for More Accurate Diagnoses
Some of the new subtypes are similar to previously identified ones but show similar prognoses to established subtypes.
FDA Approves Trastuzumab for Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
The FDA has approved trastuzumab-dttb (Ontruzant) for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma in combination with cisplatin and capecitabine or 5-fluorouracil.
FDA Approves Hepatocellular Carcinoma Therapy, Cabozantinib
The FDA has approved cabozantinib (Cabometyx) for the treatment of patients with hepatocellular carcinoma who previously received sorafenib (Nexavar).
Senescent Cell Research Shows Potential for Idiopathic Pulmonary Fibrosis
Only patients with very serious, life-threatening conditions with a risk/benefit ratio is acceptable for use of the therapy at this time.
Dipanjan Basu, PhD, Highlights Potential of Omipalisib for Neurocutaneous Melanocytosis
Dipanjan Basu, PhD, is testing non-melanoma drugs, like the investigational therapy omipalisib (GSK2126458) in cultured patient cells.
Chemotherapy Could Elevate Risk for Rare Blood Cancer
While the absolute risk of therapy-related blood cancers is low, the treatment is often intensive and linked to substantial morbidity.
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2019 Rare Disease Communications. All Rights Reserved.